Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$13.28 USD
+0.06 (0.45%)
Updated May 20, 2024 04:00 PM ET
After-Market: $13.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum B VGM
Price, Consensus and EPS Surprise
TAK 13.28 +0.06(0.45%)
Will TAK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TAK
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
TAK or CTLT: Which Is the Better Value Stock Right Now?
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Other News for TAK
Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
Google DeepMind CEO: ‘This Is the Next $100 Billion AI Business’
Takeda dengue vaccine gets WHO clearance
Biotech Alert: Searches spiking for these stocks today